lapatinib has been researched along with linagliptin in 1 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (linagliptin) | Trials (linagliptin) | Recent Studies (post-2010) (linagliptin) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 598 | 149 | 554 |
| Protein | Taxonomy | lapatinib (IC50) | linagliptin (IC50) |
|---|---|---|---|
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.3 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.2967 | |
| Dipeptidyl peptidase 4 | Homo sapiens (human) | 0.0008 | |
| Prolyl endopeptidase FAP | Mus musculus (house mouse) | 0.37 | |
| Prolyl endopeptidase FAP | Homo sapiens (human) | 0.0799 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bansal, R; Malhotra, A | 1 |
1 review(s) available for lapatinib and linagliptin
| Article | Year |
|---|---|
Therapeutic progression of quinazolines as targeted chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Enzyme Inhibitors; Humans; Molecular Structure; Neoplasms; Quinazolines | 2021 |